Osimertinib (Tagrisso)

Osimertinib is a tyrosine kinase inhibitor, which acts by blocking the activity of the epidermal growth factor receptor (EGFR). The EGFR in the lungs causes growth and uncontrolled division of cancer cells.

Osimertinib inhibits the growth of the cancer cells with T790 M mutation in the EGFR gene and acts against the metastatic EGFR T790 M mutation.

https://www.clinicaltrialsarena.com/projects/tagrisso-osimertinib-for-the-treatment-of-egfr-mutation-in-non-small-cell-lung-cancer/#:~:text=Tagrisso's%20mechanism%20of%20action,uncontrolled%20division%20of%20cancer%20cells.